The present clinical trials system cannot keep pace with the growing number of agents that merit testing. To convert more efficiently recent scientific discoveries into effective interventions, eliminate the backlog of agents for testing, and increase access for patients and individuals at risk, the capacity of the national clinical trials infrastructure must be enhanced.